A Medical Device Daily
Abbott Laboratories (Abbott Park, Illinois) said that data published in the online version of the journal Circulation from the SPIRIT III U.S. pivotal trial evaluating the Xience V Everolimus Eluting Coronary Stent System demonstrated that the Xience V outperforms the Taxus Express2 paclitaxel-eluting coronary stent system from Boston Scientific (Natick, Massachusetts) in reducing major adverse cardiac events (MACE) at two years.
In the trial, Xience V demonstrated a 45% reduction in the risk of MACE, and a 40% reduction in the risk of cardiac death or heart attack at two years in patients treated with Xience V compared to those treated with Taxus. Additionally, at two years the study demonstrated a 32% reduction in the risk of target vessel failure for Xience V compared to Taxus.
Xience V is used to treat coronary artery disease by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner to prevent the artery from becoming blocked again following a stent procedure.
The Xience V stent is available on both over-the-wire and rapid exchange delivery systems. Rapid exchange is the most widely used type of delivery system because it provides physicians additional flexibility to work as single operators during stent procedures.